Scand J Thor Cardiovasc Surg 24: 191-196, 1990
EFFECT OF DIPYRIDAMOLE (PERSANTIN@)ON BLOOD FLOW AND PATENCY OF AORTOCORONARY VEIN BYPASS GRAFTS Stig A. Ekestrom,' Sigurd Gunnes' and Ulf B. Brodin' From the 'Depurtment of Thorucic Sirrgo-y , Kurolinsktr Hospitul. und the 'L)epur.trnent of Medicul Infivmation Processing. I M I . Kurolinsktr Institrite. Stockholm. Su?~clen
Scand Cardiovasc J Downloaded from informahealthcare.com by Queen's University on 01/04/15 For personal use only.
(Accepted for publication March 5 , 1990)
Abstruct.
The effect of dipyridamole was investigated in
360 patients undergoing coronary bypass surgery. They
were randomly allocated to receive dipyridamole ( I00 mg orally q i.d. for 2 days preoperatively. 5 mgikg body weighti24 h i.v. peroperatively and 100 mg orally q.i.d. for I year postoperatively) or placebo. Withdrawn from the study were 48 patients o n dipyridamole and 57 on placebo. Cardiovascular and/or cerebrovascular events o r need for anticoagulant treatment were the reasons for withdrawal in 22 (13%) of the dipyridamole. and 34 (18%) of the placebo group. Logistic regression analysis of risk factors influencing graft patency showed significant relation to peroperatively measured coronary blood flow. A positive trend of treatment was observed @=0.08). Vein graft blood flow measured during bypass surgery (245 patients) was significantly greater in the dipyridamole group (p30 mlimin (vein-marginal p
EFFECT OF DIPYRIDAMOLE (PERSANTIN@)ON BLOOD FLOW AND PATENCY OF AORTOCORONARY VEIN BYPASS GRAFTS Stig A. Ekestrom,' Sigurd Gunnes' and Ulf B. Brodin' From the 'Depurtment of Thorucic Sirrgo-y , Kurolinsktr Hospitul. und the 'L)epur.trnent of Medicul Infivmation Processing. I M I . Kurolinsktr Institrite. Stockholm. Su?~clen
Scand Cardiovasc J Downloaded from informahealthcare.com by Queen's University on 01/04/15 For personal use only.
(Accepted for publication March 5 , 1990)
Abstruct.
The effect of dipyridamole was investigated in
360 patients undergoing coronary bypass surgery. They
were randomly allocated to receive dipyridamole ( I00 mg orally q i.d. for 2 days preoperatively. 5 mgikg body weighti24 h i.v. peroperatively and 100 mg orally q.i.d. for I year postoperatively) or placebo. Withdrawn from the study were 48 patients o n dipyridamole and 57 on placebo. Cardiovascular and/or cerebrovascular events o r need for anticoagulant treatment were the reasons for withdrawal in 22 (13%) of the dipyridamole. and 34 (18%) of the placebo group. Logistic regression analysis of risk factors influencing graft patency showed significant relation to peroperatively measured coronary blood flow. A positive trend of treatment was observed @=0.08). Vein graft blood flow measured during bypass surgery (245 patients) was significantly greater in the dipyridamole group (p30 mlimin (vein-marginal p
